Toggle light / dark theme

Many scientists research the practical and immediate applications of bio molecular technology but it seems most fail to study our most important, and largest organ, our skin.


Who will officially be the first transhuman? Will it be you? Why wait decades? This article explains one approach to speeding up the process and also the challenge involved.

Defining the Object of the Goal:

Although the words ‘cyborg’ and ‘transhuman’ are often used interchangeably, and someone can aspire to be a combination of both, there are fundamental differences between the two — as has been articulated by Dr. Natasha Vita-More: The transhuman will be genetically programmed and otherwise equipped towards indefinite life extension and to attain a great many other physical and mental capabilities and other benefits. The transhuman also maintains specific transhumanist values and may actively foster the far-reaching humane goals of the transhumanist movement, including guaranteed social justice for all and highly-advanced space colonization to foster indefinite life, peace, etc. Whereas, a cyborg may not uphold transhuman values or goals, and may or may not seek to live longer or indefinitely, but will be fitted with a device or devices to acquire one or more enhanced capabilities (such as better vision and/or hearing, faster running ability, etc.).

Read more

At the Fourth Eurosymposium on Healthy Ageing, which was held in Brussels last November, Elena and I met Dr. Kris Verburgh, a medical doctor who is especially interested in biogerontology and the potential of this field of study to turn medicine on its head.

Dr. Verburgh is only about 33 years old and has already written several science books—one of which, written when he was only 16, made him the youngest science author in Europe. Another prominent interest of his is nutrition, which he believes is one of the best, if not the best, ways we currently have to slow down the march of aging and buy ourselves more time to live until the rejuvenation age; his latest book, The Longevity Code, is centered around this topic.

Dr. Verburgh is also a strong supporter of the idea that AI will play a more and more important role in research, leading the way to a not-too-far age of personalized medicine—this was one of the theses he touched upon during the panel in which he participated at EHA.

Read more

In this interview, Dr. Leonid Peshkin offers insights on aging, the pitfalls of excessive optimism, and the role of machine learning in studying age-related disease.


Determined but not complacent, grounded but hopeful, Dr. Leonid Peshkin is one of the scientists working on understanding aging so that it may one day be treated like we treat any other ailment.

As he revealed in an interview with the Boston Globe in mid-2018, the idea of having to lose oneself and one’s loved ones to aging never made any sense to him, and ever since he was a child, he has been preoccupied with aging and the fear that it might take away his father, who was almost 60 when Leon was 10 and, sadly, passed away in July 2018 at the age of 96.

Dr. Peshkin, a 48-year-old from Moscow, Russia, possesses a master’s degree in applied mathematics and a Ph.D. in machine learning. He currently works at the Systems Biology Department at Harvard Medical School; his primary interests are embryology, evolution, and aging, which he has studied for over a decade.

Read more

Drive an hour north of Google’s headquarters up to Oyster Point, south San Francisco, and you will find the office of Calico Labs. The steel and glass building has none of the showmanship of its sister company, with its colourful, attention-grabbing Googleplex campus.

Its name is an acronym for “California Life Company” but its lifeless exterior makes it easy to imagine it being named after another Calico – an abandoned mining town further down the Pacific Coast. The company, a division of Google’s parent company Alphabet, is now five years old, but its operations remain highly secretive.


Dear friends of healthy longevity, yet another year has gone by. Hold back the melancholy though, because in this day and age a passing year can be looked at as a year fewer to wait before rejuvenation biotechnologies are available, rather than a year taken from your healthy lifespan. Busy as we are with all the errands of daily life, it is easy to forget all that’s happened and the progress we’ve made in the field in one year. So while we wait for 2019, let’s take a look back at what 2018 has brought us.

Read more

“Mikhail first approached me nearly 15 years ago with the totally crazy idea that replacing hydrogen with deuterium in bioactive molecules so as to slow down undesirable chemical reactions. Well, if ever there were a proof that some of the craziest ideas are actually right, it is this one. In the years since, Misha and his company Retrotope have taken this concept from chemistry to yeast to mice and all the way to highly promising clinical results for several hitherto untreatable orphan diseases. I’m looking forward to hearing the latest!” says Aubrey de Grey.

https://www.undoing-aging.org/news/dr-mikhail-s-shchepinov-t…aging-2019

#undoingaging #sens #foreverhealthy

Read more

A compelling study from the Weizmann Institute of Science has revealed a new anti-aging strategy designed to help the immune system remove old and dysfunctional cells from the body. The initial animal experiments promisingly restored youthful characteristics in old mice, suggesting improving immune system surveillance may be an effective anti-aging therapy.


Here, we will first summarize the experimental achievements over the last 7 years in cell and animal rejuvenation. Then, a comparison will be made between the principles of the cumulative DNA damage theory of aging and the basic facts underlying the epigenetic model of aging, including Horvath’s epigenetic clock. The third part will apply both models to two natural processes, namely, the setting of the aging clock in the mammalian zygote and the changes in the aging clock along successive generations in mammals. The first study demonstrating that skin fibroblasts from healthy centenarians can be rejuvenated by cell reprogramming was published in 2011 and will be discussed in some detail. Other cell rejuvenation studies in old humans and rodents published afterwards will be very briefly mentioned. The only in vivo study reporting that a number of organs of old progeric mice can be rejuvenated by cyclic partial reprogramming will also be described in some detail. The cumulative DNA damage theory of aging postulates that as an animal ages, toxic reactive oxygen species generated as byproducts of the mitochondria during respiration induce a random and progressive damage in genes thus leading cells to a progressive functional decline. The epigenetic model of aging postulates that there are epigenetic marks of aging that increase with age, leading to a progressive derepression of DNA which in turn causes deregulated expression of genes that disrupt cell function. The cumulative DNA damage model of aging fails to explain the resetting of the aging clock at the time of conception as well as the continued vitality of species as millenia go by. In contrast, the epigenetic model of aging straightforwardly explains both biologic phenomena. A plausible initial application of rejuvenation in vivo would be preventing adult individuals from aging thus eliminating a major risk factor for end of life pathologies. Further, it may allow the gradual achievement of whole body rejuvenation.

Read more